| Open Document File Size: 76,36 KBShare Result on Facebook
City BRISTOL / / Company SULFATE AND LAMIVUDINE TABLETS CIPLA LTD / IPR PHARMACEUTICALS INC / ASPARAGINASE ERWINIA CHRYSANTHEMI EUSA PHARMA (USA) INC. / SHARP AND DOHME CORP / ZYTIGA ABIRATERONE ACETATE CENTOCOR ORTHO BIOTECH INC / BENLYSTA BELIMUMAB HUMAN GENOME SCIENCES INC. / INJECTION GE HEALTHCARE INC / HOLOGIC INC / RITONAVIR TABLETS MYLAN LABORATORIES LTD / DIFICID FIDAXOMICIN OPTIMER PHARMACEUTICALS INC / TELAPREVIR VERTEX PHARMACEUTICALS INC / HEALTHCARE INC HOPE PHARMACEUTICALS / OXYMORPHONE HYDROCHLORIDE ENDO PHARMACEUTICALS INC / OXYCODONE HCL KING PHARMACEUTICALS / / Event FDA Phase / / MedicalCondition CANCER / disease / / Product OPANA ER / LAMIVUDINE / ISENTRESS / F-18 / PREZISTA / ABACAVIR SULFATE / NITROGLYCERIN / ATAZANAVIR SULFATE / RITONAVIR TABLETS / SODIUM THIOSULFATE / ABACAVIR SULFATE AND LAMIVUDINE TABLETS / ATAZANAVIR SULFATE AND RITONAVIR TABLETS / NDA / VICTRELIS™ BOCEPREVIR / / ProgrammingLanguage L / / PublishedMedium Public Law / /
SocialTag |
CDER Priority Drug and Biologic Approvals in Calendar Year 2011